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Background: A majority of autoimmune diseases, including systemic lupus erythematosus (SLE), occur predominantly
in females. Recent studies have identified specific dysregulated microRNAs (miRNAs) in both human and murine lupus,
implying an important contribution of these miRNAs to lupus pathogenesis. However, to date, there is no study that
examined sex differences in miRNA expression in immune cells as a plausible basis for sex differences in autoimmune
disease. This study addresses this aspect in NZB/WF1 mice, a classical murine lupus model with marked female bias, and
further investigates estrogen regulation of lupus-associated miRNAs.
Methods: The Taqman miRNA assay system was used to quantify the miRNA expression in splenocytes from
male and female NZB/WF1 mice at 17–18, 23, and 30 weeks (wks) of age. To evaluate potential estrogen's effect
on lupus-associated miRNAs, 6-wk-old NZB/WF1 male mice were orchidectomized and surgically implanted with
empty (placebo) or estrogen implants for 4 and 26 wks, respectively. To assess the lupus status in the NZB/WF1
mice, serum anti-dsDNA autoantibody levels, proteinuria, and renal histological changes were determined.
Results: The sex differences in the expression of lupus-associated miRNAs, including the miR-182-96-183 cluster,
miR-155, miR-31, miR-148a, miR-127, and miR-379, were markedly evident after the onset of lupus, especially at
30 wks of age when female NZB/WF1 mice manifested moderate to severe lupus when compared to their male
counterparts. Our limited data also suggested that estrogen treatment increased the expression of aforementioned
lupus-associated miRNAs, with the exception of miR-155, in orchidectomized male NZB/WF1 mice to a similar level in
age-matched intact female NZB/WF1 mice. It is noteworthy that orchiectomy, itself, did not affect the expression of
lupus-associated miRNAs.
Conclusion: To our knowledge, this is the first study that demonstrated sex differences in the expression of
lupus-associated miRNAs in splenocytes, especially in the context of autoimmunity. The increased expression
of lupus-associated miRNA in female NZB/WF1 mice and conceivably in estrogen-treated orchidectomized male
NZB/WF1 mice was associated with lupus manifestation. The notable increase of lupus-associated miRNAs in
diseased, female NZB/WF1 mice may be a result of both lupus manifestation and the female gender.
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Sex differences in gene expression have physiological
and pathological implications. Not only sex chromosome-
linked genes but also autosomal genes are differentially
expressed between males and females. It is noteworthy
that sex chromosome-linked genes only count for a
small number of sexually dimorphic genes; a majority
of the sex differentially expressed genes are located on
the autosomes since they possess about 95% of genes
[1,2]. Sex differences in gene expression are regulated
by a complex network comprising of sex chromosomes,
sex hormones, and other sex-biased factors. Indeed, a
new term, “sexome”, has been coined to encompass the
sum of sex-biased effects on gene networks and cell
systems [3]. Recently, much attention has been focused
on the epigenetic regulation of gene expression in the
context of physiological and pathological conditions.
Epigenetic mechanisms such as DNA methylation, histone
modification, and microRNAs (miRNAs) have been
proposed to understand sex differences in gene expression
and in susceptibility to a broad range of human diseases
including autoimmune diseases such as lupus [1,4-7].
miRNAs are short (about 22 nucleotides long), non-
coding RNAs that regulate gene expression mainly at
the post-transcriptional level by binding to the 3' UTR
of target genes and inducing translational inhibition
or degradation of the target mRNA [8,9]. miRNAs
are predicted to regulate up to 90% of human genome
and thereby function as key regulators of almost all
physiological systems to maintain cellular homeostasis
and functions [10,11]. Thus, it is not surprising that
dysregulated miRNAs have been identified and implicated
in various human pathological conditions, including
autoimmune-related disorders [9,12-15]. With a better
understanding of the critical roles of miRNAs in disease
pathogenesis, miRNAs are rapidly being considered as a
new type of gene therapeutic target for treating diseases
[12,16]. There are several studies that show sex differences
of miRNA expression in gonadal tissues such as ovary
and testis [17], and also in somatic tissues such as liver
[18]. This suggests a potential contribution of miRNA
regulation to the observed sexual dimorphism of gene
expression and function. However, to our knowledge,
thus far there is no study that has examined sex differences
in miRNA expression in immune cells in the context
of autoimmune disease.
It has been recognized for a long time that males and
females have different immune capabilities and that
they display different degrees of susceptibility to various
diseases including autoimmune-related disorders [19-23].
In general, females are more susceptible to autoimmune
conditions than males [19,20]. In women 65 years and
younger, autoimmune diseases are among the top ten
causes of all deaths and the fourth largest cause ofdisability [24,25]. Systemic lupus erythematosus (SLE or
lupus) occurs 9–13 times more frequently in women
compared to men, with over 90% of lupus patients
being women. In addition to the critical contribution
of genetic factors such as sex chromosome-linked genes,
X chromosome monosomy, and skewed X chromosome
inactivation [26,27], other factors such as hormonal and
environmental factors are thought to interact with genetic
factors, leading to the female prevalence of autoimmune
diseases such as lupus [19,28-30]. One such mechanism
by which hormonal and environmental factors regulate
autoimmunity is through the regulation of miRNA ex-
pression [31].
NZB/WF1 is a well-characterized classical murine
model for human lupus. Marked sex differences in the
expression of lupus in this model are evident. Female
NZB/WF1 mice develop moderate to severe lupus months
earlier than their male counterparts. Manipulation of
NZB/WF1 mice with sex hormones profoundly alters
the disease course [32,33]. For example, administration
of female hormone estrogen to male NZB/WF1 mice
exacerbates lupus to a level that is comparable to sus-
ceptible females [33]. We recently reported that female
NZB/WF1 mice had increased expression of lupus-
associated miRNAs such as the miR-182-96-183 cluster,
miR-31, miR-155, miR-127, and miR-379 only at an
age when lupus is manifested [34]. miR-148a showed
increased expression in female NZB/WF1 even before
the onset of lupus [34]. The potential contribution of
these individual miRNAs to autoimmune diseases has
been suggested in recent studies. Among the above
lupus-associated miRNAs, miR-31 and miR-148a were
reported to be dysregulated in human lupus patients and
contributed to human lupus pathogenesis by affecting
IL-2 production and by causing CD4+ T cell hypome-
thylation and induction of autoimmune-associated genes,
respectively [35,36]. miR-155 is a well-studied miRNA
that plays critical roles in the regulation of both innate
and adaptive immune cell development and function.
miR-155 has been shown to contribute to the patho-
genesis of experimental autoimmune encephalomyelitis
(EAE) and rheumatoid arthritis by affecting inflamma-
tory Th17 and Th1 cell development and function
[37,38]. However, the role of miR-155 in lupus patho-
genesis remains elusive [14,39]. miR-182 plays a critical
role in the regulation of activated Th cell proliferation
and clonal expansion, but its contribution to autoimmune
disease pathogenesis is still not clear. There is also
limited knowledge with regard to the immune regulatory
function of miR-127 and miR-379.
In this study, we utilized both female and male NZB/
WF1 mice to address two fundamental questions. First,
given that there are marked sex differences in suscepti-
bility to lupus, are there comparable sex differences in
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since estrogen accelerates lupus in male NZB/WF1 mice,
does estrogen treatment promote the expression of
lupus-associated miRNAs? Our study clearly showed
that female NZB/WF1 mice displayed increased expression
levels of lupus-associated miRNAs after the onset of
lupus when compared to age-matched males. Importantly,
these miRNAs were disease-associated and were up-
regulated by estrogen treatment. Our novel findings of
sexual differential expression and estrogen regulation
of miRNAs in the context of lupus provide a new per-




Male and female NZB/WF1 mice (stock number 100008)
were purchased from the Jackson Laboratory (Bar Harbor,
ME, USA). All mice were housed in the phase IV ani-
mal facility of Virginia-Maryland Regional College of
Veterinary Medicine, Virginia Tech. All procedures were
approved by the Virginia Tech Institutional Animal Care
and Use Committee (IACUC). The male and female NZB/
WF1 mice were euthanized at 17/18, 23, and 30 weeks
(wks) of age, respectively, and the spleen tissues were
collected to isolate the splenocytes.
To determine the effect of female hormone estrogen
on lupus-associated miRNA expression, per our previous
published procedure [40-42], 6-wk-old male NZB/WF1
mice were orchidectomized and then surgically implanted
with empty (placebo) or estrogen silicon implants. Con-
sidering the potential effect of orchiectomy on miRNA
expression, we included a group of age-matched NZB/
WF1 male mice that were not subjected to surgery and
implant treatment (intact group). Different groups of mice
were euthanized at 10 and 32 wks of age, after receiving
4 and 26 wks of implant treatment, respectively. The
age-matched intact male mice were euthanized at the
same time to serve as intact control.
Splenocyte preparation
Whole splenocytes were isolated using standard lab proce-
dures described in detail previously [34,40-43]. In brief,
the spleens were dissociated by gently scraping through
a steel screen, and the cell suspension was passed
through a 70-μm cell strainer to remove undissociated
tissue debris. The splenocytes were isolated by lysing
red blood cells with ACK-Tris-NH4Cl buffer and then
washing with complete RPMI-1640 medium (Mediatech,
Inc., Manassas, VA, USA) that was supplemented with
10% charcoal-stripped fetal bovine serum (Atlanta Bio-
logicals, Flowery Branch, GA, USA), 2 mM L-glutamine
(Mediatech, Inc.), 100 IU/ml penicillin and 100 μg/ml
streptomycin (Mediatech, Inc.), and 1% non-essentialamino acids (Mediatech, Inc.). Freshly prepared spleno-
cytes were pelleted and stored at −80°C for RNA isolation.
Quantification of miRNA expression
Total RNA, containing small RNA, was isolated from
the whole splenocytes using miRNeasy Mini Kit (Qiagen,
Valencia, CA, USA). On-column DNase digestion with
RNase-free DNase (Qiagen) was performed to remove
residual amounts of DNA contamination in the isolated
RNA. The RNA concentration was quantified using a Nano-
Drop 2000 (Thermo Fisher Scientific Inc., Wilmington,
DE, USA). As we described previously [34,42], Taqman
miRNA assay reagent (Applied Biosystems, Grand Island,
NY, USA) was used to quantify the miRNA expression
per manufacturer's instructions. The expression level of
miRNA was normalized to small RNA housekeeping
control snoRNA 202. The data was shown as relative
expression level to an appropriate control group by
using the 2−ΔΔCt formula (Livak method).
Assay of serum anti-dsDNA autoantibodies
The male and female NZB/WF1 mice were aged in our
facility and bled retro-orbitally every 2 to 4 wks after
they reached 16 or 18 wks of age. The serum anti-
dsDNA antibody levels were measured by ELISA per our
previous reports [34]. Briefly, the ELISA plate was coated
overnight with 100 μg/ml calf thymus dsDNA (Sigma-
Aldrich, St. Louis, MI, USA). After washing, the plate
was blocked with PBS and 1%BSA, incubated with serum
samples, followed by incubation with HRP conjugated
goat-anti mouse IgG-gamma (Sigma), and lastly TMB
substrate for signal development (KPL, Inc., Gaithersburg,
MD, USA). The absorbance was measured by reading
the plate at 380 nM with a SpectraMax M5 Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA).
Measurement of proteinuria
Proteinuria was measured by dipstick analysis using
Chemistrip-2GP (Roche Diagnostics Corporation, In-
dianapolis, IN, USA). The semi-quantitative scale was
demonstrated as follows: “−”, negative or trace; “+”, 30
mg/dl; “+/−”, 30–100 mg/dl; “++”, 100 mg/dl; “++/−”,
100–500 mg/dl; and “+++”, 500 mg/dl or over.
Renal histopathology
As previously described [34], the kidneys from the
NZB/WF1 mice were collected and fixed in 10% buff-
ered formalin and embedded in paraffin. Five-micron
sections were stained with hematoxylin and eosin (H&E)
or periodic acid-Schiff (PAS) in the histopathology lab
at VMRCVM, Virginia Tech. The stained renal sections
were assessed by Dr. Tanya LeRoith, a board certified
pathologist, in a blinded fashion. A grade of 0 to 4 (0 =
perfect, no change; 1 = minimal; 2 = moderate; 3 =
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lar, tubular, interstitial, and vessel inflammation and
lesions, respectively. By adding the scores together, we
derived an overall renal score for the microscopic
changes in each sample.
Statistical analysis
All the values in the graphs were depicted as means ±
SEMs. Student t test and one-way ANOVA with Tukey-
Kramer all pair's comparisons were performed to assess
the statistical significance of miRNA expression between
two groups and among the multiple groups, respectively.
The JMP software (Pro10) from SAS Institute Inc. (Cary,
NC, USA) was used for statistical analysis.
Results
Before the onset of lupus, male and female NZB/WF1 mice
have comparable levels of lupus-associated miRNAs
In our previous study where we utilized only female
NZB/WF1 mice, we reported that a set of miRNAs
including the miR-96-182-183 cluster, miR-155, miR-31,
miR-127, and miR-379 were upregulated only in the
splenocytes from diseased 36–40-wk-old (8–9 months)
female NZB/WF1 mice, but not in the splenocytes from
the pre-diseased 16–18-wk-old (3–4 months) NZB/WF1
mice when compared to those in the control NZW
mice [34]. In this study, given that there are marked
sex differences in the expression and course of lupus in
NZB/WF1 mice, we utilized both male and femaleFigure 1 Comparable lupus-associated miRNA levels in splenocytes fr
Real-time RT-PCR analysis of select lupus-associated miRNAs. The graph rep
(male vs female). *p < 0.05. (B) ELISA assay of serum anti-dsDNA autoantib
were included as negative control. The mean serum anti-DNA autoantibodNZB/WF1 mice to determine whether there is also sexual
differential expression of aforementioned lupus-associated
miRNAs.
We initially analyzed the expression of lupus-associated
miRNAs including the miR-96-182-183 cluster, miR-155,
miR-31, miR-127, miR-379, and miR-148a in splenocytes
from male and female NZB/WF1 mice at 17–18 wks old,
an age before the onset of disease in NZB/WF1 mice.
As shown in Figure 1A, there was no significant difference
in the expression of miR-182-96-183 cluster, miR-155,
miR-31, and miR-148a between male and female mice.
There was a slight, but significant increase of miR-127
and miR-379 in 17–18-wk-old female NZB/WF1 mice
when compared to the male counterparts. As expected,
there was no detection of serum anti-dsDNA antibodies
in either 17–18-wk-old male or female NZB/WF1 mice
(Figure 1B).
After the onset of lupus, female NZB/WF1 mice have
increased expression of lupus-associated miRNA in
splenocytes compared to male counterparts
We next analyzed the aforementioned lupus-associated
miRNAs in male and female NZB/WF1 mice at 23 and
30 wks of age. During this age, female, but not male
NZB/WF1 mice, begin to develop mild to severe lupus
disease. At 23 wks of age, the expression levels of
miR-182, miR-183, miR-127, and miR-31 were significantly
increased in female NZB/WF1 mice when compared to
age-matched male NZB/WF1 mice (Figure 2A). Theom male and female NZB/WF1 mice before lupus onset. (A)
resents the means ± SEMs (n = 4 each). Student t test was performed
odies. The serum samples from three non-autoimmune C57/BL6 mice
y value in each group was indicated by black line.
Figure 2 Sex differences in the expression of lupus-associated miRNAs become evident after onset of lupus. (A) Real-time RT-PCR analysis
of lupus-associated miRNAs expression in splenocytes. The expression level of a specific miRNA in 23-wk-old female and 30-wk-old male and fe-
male NZB/WF1 mice was shown as the relative expression level to 23-wk-old male mice. The graphs represent the means ± SEMs (n = 5 each for
23-wk-old male and female mice groups, and n = 4 each for 30-wk-old male and female mice groups). Student t test was performed (age-
matched male vs female, and sex-matched 23 wks vs 30 wks). *p < 0.05 and **p <0.01. (B and C) Anti-dsDNA autoantibody ELISA. Anti-dsDNA
antibody levels were monitored sequentially every 2–4 wks in individual male (dashed blue hue lines) and female (solid pink hue line) NZB/WF1
mice that were terminated at (B) 23 wks of age and (C) 30 wks of age, respectively.
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with the exacerbation of lupus in 30-wk-old female NZB/
WF1 mice (Figure 2A). We noticed that the expression
of miR-96, miR-379, and miR-148a was significantly
increased in 30-wk-old female mice, but not in 23-wk-old
female mice when compared to that in age-matched
male mice (Figure 2A). There was a trend of increase of
miR-155 in 30-wk-old female mice when compared to
age-matched male mice. It is noteworthy that we only
observed a significant increase of lupus-associated miR-
NAs in 30-wk-old female, but not in 30-wk-old male
NZB/WF1 mice when compared to their respective23-wk-old, sex-matched controls. This suggests that the
upregulation of these miRNAs in 30-wk-old female
NZB/WF1 mice was not simply an aging effect, but
rather was associated with lupus manifestation in
female mice.
Assessment of serum anti-dsDNA autoantibodies in male
and female NZB/WF1 mice
To monitor lupus development and severity in NZB/
WF1 mice, we measured the serum levels of anti-dsDNA
autoantibodies (a hallmark of lupus) sequentially. Two
groups of male and female NZB/WF1 mice were utilized
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bled from 16 wks of age as indicated and terminated at
23 wks of age for experimental assay (Figure 2B). The
mice in the second group were sequentially bled from 18
wks of age and terminated at 30 wks of age (Figure 2C).
It is apparent that in both groups of mice, only the
female NZB/WF1 mice demonstrated detectable levels
of anti-dsDNA autoantibodies by 18 wks of age. Auto-
antibodies against dsDNA in the first cohort of female
mice continued to increase by 23 wks of age when the
mice were terminated (Figure 2B). In the second cohort
of mice, the anti-dsDNA autoantibodies also continued
to increase by 24 wks of age, but two females (30-wk
F3 and 30-wk F4) demonstrated a sharp decline of anti-
dsDNA autoantibodies in sera by 30 wks of age (Figure 2C).
It is quite likely that in these two mice, the autoantibodies
were directed to lupus target organs such as kidneys to
induce glomerulonephritis. In support of this view,
these two female mice (30-wk F3 and 30-wk F4) had a
significant degree of glomerulonephritis and high level
of proteinuria (over 500 mg/dl) at 30 wks of age
(Table 1). In contrast to the female mice, the majority
of male mice did not begin to develop anti-dsDNA
autoantibodies by 30 wks of age. Overall, the female
NZB/WF1 mice had an earlier production and higher
levels of anti-dsDNA autoantibodies when compared to
age-matched male counterparts.
Evaluation of renal pathology in male and female
NZB/WF1 mice
Since kidney is the major target organ for immune
complex glomerulonephritis in lupus, we therefore
analyzed the renal pathological changes in NZB/WF1
mice that were terminated at 23 and 30 wks of age. It
was not surprising that there were no or only minimal
histological changes in the kidneys of NZB/WF1 at 23
wks of age (Table 1 and Figure 3) since at this age,
female mice were just beginning to develop detectable
levels of anti-dsDNA autoantibodies. Conceivably, protein-
uria was not detected in 23-wk-old NZB/WF1 mice
(Table 1). By 30 wks of age, in male NZB/WF1 mice,
there was no or minimal tissue inflammation (Table 1).Table 1 Renal pathological changes in male and female NZB/
Male 23 wks Femal
Mouse ID #1 #2 #3 #4 #5 #1 #2 #3
Glomerular scorea 0 0 0 1 1 0 1 0
Tubular scorea 0 0 0 0 0 0 0 1
Interstitial scorea 0 1 0 0 0 0 0 0
Vessel scorea 0 0 0 0 0 0 0 0
Overall renal score 0 1 0 1 1 0 1 0
Proteinuriab +/− +/− + − − + +/− −
a0 = perfect, no change; 1 = minimal; 2 = moderate; 3 = marked; and 4 = severe; bnIn contrast to males, 30-wk-old female NZB/WF1 mice
(30-wk F3 and F4) demonstrated moderate to marked
renal inflammation and damages including membrano-
proliferative glomerulonephritis, protein casts, and had
high levels of proteinuria (Table 1 and Figure 3). The
female mouse F2, which did not develop anti-dsDNA
autoantibodies until 30 wks of age, had no notable renal
histological change. Taken together, our data indicated
that female NZB/WF1 mice had earlier and more severe
lupus manifestation than age-matched male counterparts.
Estrogen regulation of lupus-associated miRNAs
In our previous study, we have shown that estrogen
regulates inflammatory responses by modulating the
expression of selected miRNAs in splenocytes of orchi-
dectomized wild-type C57BL/6 (B6) male mice [42]. Since
estrogen has been well documented to exacerbate lupus,
especially in NZB/WF1 murine model [32,33], we in-
vestigated whether estrogen regulates lupus-associated
miRNAs expression in NZB/WF1 mice. We examined
estrogen's effect on miRNA expression after 4 and 26
wks of estrogen treatment (the mice were 10-wk-old
and 32-wk-old, respectively, at the time when they were
terminated). As shown in Figure 4A, there was no sig-
nificant increase of most lupus-associated miRNAs in
10-wk-old estrogen-treated orchidectomized mice when
compared to age-matched intact or placebo-treated
orchidectomized mice. The only exception is miR-379,
which was increased in the splenocytes from 10-wk-old
estrogen-treated mice. miR-182-96-183, miR-379, and
miR-148a were significantly increased in 32-wk-old
estrogen-treated mice when compared to either age-
matched intact or placebo-treated mice. There was a
trend (albeit not significant) of increase of miR-31 and
miR-127 expressions in 32-wk-old estrogen-treated mice
when compared to 32-wk-old placebo-treated control
mice. Interestingly, estrogen treatment did not affect
the expression of miR-155. Together, our data indicate
that estrogen treatment promoted the expression of
lupus-associated miRNAs with the exception of miR-155
in splenocytes from NZB/WF1 mice. It is noteworthy to
point out that orchiectomy itself did not affect theWF1 mice
e 23 wks Male 30 wks Female 30 wks
#4 #5 #1 #2 #3 #4 #1 #2 #3 #4
0 0 0 0 0 0 1 0 2 3
0 0 0 0 0 0 0 0 2 3
1 0 0 0 0 0 0 0 2 3
0 0 0 1 1 1 1 0 1 2
1 0 0 1 1 1 2 0 7 11
− + + − − ++ ++ + +++ +++
egative or trace, −; 30, +; 30–100, +/−; 100, ++; 100–500, ++/−, 500, +++.
Figure 3 Renal pathology of male and female NZB/WF1 mice. Renal sections from 23-wk-old and 30-wk-old male and female NZB/WF1 mice
were stained with H&E and PAS, respectively. Representative images from each age and gender group were shown. Note that only the 30-wk-old
female NZB/WF1 mice demonstrated moderate to severe mesangioproliferative glomerulonephritis and tubular protein casts (indicated by arrow).
The mice in the other groups showed no or minimal glomerular inflammation.
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no difference in the expression levels of these miRNAs
between placebo-treated orchidectomized and intact
control mice.
Assessment of autoimmune parameters in placebo- and
estrogen-treated orchidectomized male NZB/WF1 mice
We measured the serum anti-dsDNA antibody levels in
all the orchidectomized mice that were subjected to
placebo or estrogen treatment for 4 or 26 wks. The age-
matched intact control males were assessed at the same
time. As expected, there was no detection of anti-dsDNA
autoantibodies in all 10-wk-old NZB/WF1 mice with or
without implant treatment (Figure 4B). In 32-wk-old
intact male NZB/WF1 mice, we detected moderate
levels of anti-dsDNA antibodies, which were similar to
what we have observed in 30-wk-old NZB/WF1 male
mice. In contrast, 32-wk-old estrogen-treated mice had
noticeable higher levels of anti-dsDNA autoantibodies(Figure 4B). For placebo-treated NZB/WF1 mice, three
mice had basal levels of anti-dsDNA autoantibodies,
and the other two mice had high levels of anti-dsDNA
antibodies (Figure 4B). We noticed that individual mice
from 32-wk-old intact, placebo-, and estrogen-treated
groups had minimal to moderate renal inflammation
and glomerulonephritis (Table 2). Even though two
placebo-treated mice had high levels of anti-dsDNA
autoantibodies that were comparable to estrogen-treated
mice, there was no marked increase of lupus-associated
miRNA expression in these two placebo-treated mice.
We only observed a significant increase of lupus-associated
miRNAs in estrogen-treated orchidectomized NZB/
WF1 mice. This suggests that enhanced anti-dsDNA
autoantibody levels do not closely reflect the increase
of lupus-associated miRNAs. The increase of lupus-
associated miRNAs in estrogen-treated mice might be
due to a combination of disease manifestation and es-
trogen effect.
Figure 4 Estrogen regulation of lupus-associated miRNAs expression in splenocytes from orchidectomized NZB/WF1 mice. (A) Real-time
RT-PCR analysis of miRNA expression in splenocytes from 10-wk-old and 32-wk-old intact male, placebo- and estrogen-treated orchidectomized male
NZB/WF1 mice. The expression level of a specific miRNA in all other groups was shown as relative level to the 10-wk-old intact male mice. The graphs
represent the means ± SEMs (n = 4 each for 10-wk-old intact and placebo-treated mice groups, n = 5 each for 10-wk-old estrogen-treated, 32-wk-old
intact, and 32-wk-old placebo-treated mice groups, and n = 2 for 32-wk-old estrogen-treated mice group). One-way ANOVA with Tukey-Kramer all
pair's comparison tests were performed to compare the expression among the age-matched intact, placebo-, and estrogen-treated mice.
Asterisk indicates the statistical significance between the age-matched placebo control and estrogen-treated mice, and the number sign indicates the
statistical significance between the age-matched intact control and estrogen-treated mice. Asterisk and number sign depict p < 0.05; double asterisk and
double number sign depict p < 0.01. (B) Anti-dsDNA autoantibody ELISA. The figure shows the serum anti-DNA autoantibody levels in NZB/WF1 male
mice from aforementioned six treatment groups. Four C57BL6/ mice were included as negative controls. The bold black line represents the mean serum
autoantibody value of each group.
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In this study, we observed that short-term estrogen
treatment (4 wks) did not increase miR-148a (Figure 4A),
which has been shown to be upregulated by estrogen in
orchidectomized wild-type B6 mice [42]. One possible
explanation is that 4 wks of estrogen treatment was not
sufficient to alter the expression of the miRNAs that wereanalyzed in this study. To confirm the time dependence of
estrogen effect on miRNA expression in NZB/WF1 mice,
we analyzed the expression of miR-223 and miR-451,
which were markedly upregulated by estrogen in wild-type
B6 mice [42]. As expected, the expression levels of
miR-223 and miR-451 were significantly upregulated in
both 10-wk-old (Figure 5A) and 32-wk-old (Figure 5B)
Table 2 Renal evaluation of 32-wk-old intact, placebo-, and estrogen-treated orchidectomized NZB/WF1 mice
Intact 32 wks Placebo 32 wks Estrogen 32 wks
Mouse ID #1 #2 #3 #4 #5 #1 #2 #3 #4 #5 #1 #2
Glomerular scorea 1 2 0 0 0 1 1 0 0 2 0 2
Tubular scorea 1 1 1 1 2 1 1 1 1 0 1 1
Interstitial scorea 0 0 0 0 0 2 0 0 0 0 0 1
Vessel scorea 1 0 0 0 0 1 1 0 0 2 0 1
Overall renal score 3 3 1 1 2 5 3 1 1 4 1 5
Proteinuriab +/− +/− − + +/− +/− ++ +/− +/− + − ++/−
a0 = perfect, no change; 1 = minimal; 2 = moderate; 3 = marked; and 4 = severe; bnegative or trace, −; 30, +; 30–100, +/−; 100, ++; 100–500, ++/−, 500, +++.
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intact or placebo-treated mice. Unlike lupus-associated
miRNAs such as the miR-182 cluster that was highly
increased in diseased, 36–40-wk-old NZB/WF1 mice [34],
miR-223 and miR-451 were not significantly increased in
36–40-wk-old female NZB/WF1 mice when compared to
pre-diseased NZB/WF1 or NZW control (Additional file 1:
Figure S1). This suggests that the remarkable increase
of miR-223 and miR-451 in 32-wk-old estrogen-treated
mice was attributable to estrogen effect, but not to lupus
manifestation. It is noteworthy that the magnitude of
miR-223 (about 2-fold) and miR-451 (about 6-fold)
increase in 10-wk-old estrogen-treated NZB/WF1 mice
was further increased in 32-wk-old estrogen-treated
NZB/WF1 (over 5-fold for miR-223 and over 20-fold for
miR-451) when compared to those in intact controls
(Figure 5). This data further suggested a potential time
effect of estrogen treatment on the expression of miRNAs.
We then compared the expression level of lupus-
associated miRNAs in 32-wk-old, estrogen-treated orchid-
ectomized male NZB/WF1 mice with that in intact female
NZB/WF1 mice at a similar age (30 wks old, Figure 6).
Impressively, the expression levels of lupus-associated
miRNAs in estrogen-treated orchidectomized male NZB/
WF1 mice were comparable to those in 30-wk-old female
NZB/WF1 mice. The only exception was miR-155, whichFigure 5 Estrogen increased the expression of miR-223 and miR-451
increased miR-223 and miR-451 expression in splenocytes from 10-wk-old (A)
when compared to either age-matched placebo control or intact control mic
treated mice group, and n = 4 each for the other groups). Student t test waswas not regulated by estrogen treatment (Figure 4).
Overall, our data indicated that estrogen treatment
promoted the expression of lupus-associated miRNAs
(except miR-155) in NZB/WF1 male mice to a similar
level as that in age-matched female mice. This suggests
that estrogen-induced acceleration of lupus in male NZB/
WF1 mice might be associated with enhanced expression
of select lupus-associated miRNAs.
Discussion
The sexual dimorphisms of genome structure and gene
regulation imply the sex difference in susceptibility to
human disease such as autoimmune disease, which dis-
proportionally affect women [7]. There is now a flurry of
recent reports documenting the critical role of non-coding
miRNAs in the control of autoimmunity [9,14,15,44,45].
However, thus far, there is no study that addresses
whether there are sex differences in miRNA expression
as a plausible explanation for the sex bias of autoimmune
diseases. In this study, we examined whether previously
identified lupus-associated miRNAs are differentially
expressed in gonadal intact male and female NZB/WF1
mice. Considering that estrogen plays an important role
in the female prevalence and severity of murine lupus,
we further investigated whether estrogen augments the
expression of lupus-associated miRNAs in NZB/WF1 mice.expression in splenocytes from NZB/WF1 mice. The graphs show
and 32-wk-old (B) estrogen-treated orchidectomized NZB/WF1 mice
e. The graph shows the means ± SEMS (n = 2 for 32-wk-old, estrogen-
performed (estrogen vs placebo or intact). *p < 0.05 and *** p <0.001.
Figure 6 Comparable lupus-associated miRNAs levels in splenocytes from estrogen-treated male and age-matched intact female NZB/
WF1 mice. The expression levels of miRNA in 30-wk-old intact female and 32-wk-old estrogen-treated orchidectomized NZB/WF1 mice were shown as
the relative expression levels to 30-wk-old intact male mice. The graph shows the means ± SEMS (n = 2 for 32-wk-old estrogen-treated mice
group, and n = 4 each for 30-wk-old intact male and female mice groups). Student t test was performed (30-wk-old female NZB/WF1 vs 32-wk-old
estrogen-treated orchidectomized NZB/WF1). *p < 0.05.
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the expressions of lupus-associated miRNAs (miR-182-
96-183, miR-31, miR-127, miR-379, and miR-148a, miR-
155) were significantly increased in female NZB/WF1
mice when compared to those in age-matched male
mice. The sex differences in the expression of the above
miRNAs became more prominent at 30 wks of age
when moderate and marked lupus was evident in the
female NZB/WF1 mice (Figure 2A). The autoimmune
statuses were confirmed in 30-wk-old female NZB/WF1
mice as indicated by the increased anti-dsDNA auto-
antibodies (Figure 2C), proteinuria, and marked renal
pathological changes when compared to those in male
counterparts (Figure 3 and Table 1). It is noteworthy
that the expression levels of most lupus-associated
miRNAs in pre-diseased (17–18 wk old) female NZB/
WF1 mice were comparable to those in male counterparts
(Figure 1). Further, our findings tend to support the
proof of principle that estrogen can augment lupus-
associated miRNAs (with the exception of miR-155) in
relatively resistant males (Figure 4).
Our finding of increased miR-182 cluster, miR-155,
miR-31, and miR-148a expression in female NZB/WF1
mice at an age after the onset of lupus validates our
previous report of the association of these miRNAs
with lupus manifestation in this model. Thus far, the
potential contribution of the miR-182-96-183 cluster to
lupus remains elusive. miR-182 is substantially increased
in activated T cells, which is critical for the proliferation
and expansion of activated T helper (Th) cells [46]. The
direct link between miR-182 and autoimmune inflam-
mation is not definitive thus far. However, its role in
autoimmunity is suggested by the finding that the
inhibition of miR-182 in T cells reduced ovalbumin
(OVA)-induced arthritis in mice [46]. Moreover, our
unpublished data revealed that the inhibition of this
miRNA cluster in murine lupus splenocytes significantlydepressed the production of inflammatory cytokines that
are implicated in lupus pathogenesis. miR-148a was the
only miRNA that displayed the increased expression in
pre-diseased female NZB/WF1 mice when compared to
those in NZW controls [34]. Its expression was further
increased in 36–40-wk-old female NZB/WF1 mice ac-
companying lupus progression (unpublished data). The
finding of increased miR-148a in female mice at 30 wks
of age is significant since miR-148a was reported to be
highly upregulated in both human and murine lupus T
cells, which contributed to DNA hypomethylation and
induction of autoimmune-associated genes by targeting
DNA methyltransferase 1 (DNMT1) [36]. We observed
an increase of miR-31 in splenocytes from murine lupus,
which may contribute to autoimmunity by suppressing
regulatory T cell (Treg) development or function as it was
reported to target Foxp3, a lineage specific transcription
factor for Tregs [47]. Unlike our finding in murine
lupus models, human lupus peripheral blood T cells had
decreased miR-31 expression, which correlated with
reduced IL2 production in human lupus T cells [35].
Of the eight lupus-associated miRNAs analyzed in
this study, only miR-127 and miR-379 displayed sexual
differential expression before the onset of lupus in
NZB/WF1 (Figure 1). Interestingly, we found that only
miR-379 was increased in splenocytes from 4 wks of
estrogen-treated orchidectomized NZB/WF1 mice when
compared to placebo-controls (Figure 4A). miR-127
and miR-379 are encoded by a large miRNA cluster
embedded in the mouse maternal imprinted region Dlk1-
Gtl2 and human homologues DLK1-DIO3. Impressively,
our previous microarray data indicated that in addition
to miR-127 and miR-379, several other miRNAs from
the Dlk1-Gtl2 region, including miR-433, miR-300, and
miR-382, were also increased in MRL-lpr and B6-lpr
mice [34]. So far, there is limited knowledge about
Dlk1-Gtl2 imprinted miRNA clusters such as miR-127
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their immune regulatory function. Further investigation is
warranted to understand the contribution of Dlk1-Gtl2
(or human DLK1-DIO3) genomic imprinted miRNAs
to autoimmune disorders.
Even though the effect of estrogen on human lupus
is still debatable, estrogen undoubtedly induces earlier
onset of lupus and exacerbates lupus severity in murine
lupus models, especially in NZB/WF1 [32,33]. We have
reported that estrogen-modulated miRNA expression
in orchidectomized wild-type B6 mice [42]. Importantly,
estrogen-downregulated miRNAs such as miR-146a
and miR-125 were also shown to be depressed in
PBMC or CD4+ T cells from human lupus patients and
inversely correlated with lupus activity [44,48]. The
estrogen-upregulated miRNA miR-148a was increased
in CD4 T cells from human lupus patients and positively
correlated with lupus activity [49]. This suggested a
potential effect of estrogen on lupus by regulating the
expression of lupus-associated miRNAs.
Previous reports have documented that pre-pubertal
castration and estrogen treatment of male NZB/WF1 mice
greatly enhanced mortality (60% by age of 28 wks old)
[33]. In our study, we lost about 55% of estrogen-treated
mice (five out of nine mice) by the age of 32 wks. At
this age, all mice belonging to the intact control and
placebo-treated groups survived. Among the four estrogen-
treated mice that survived to 32 wks of age, two mice
developed severe lymphoma in addition to lupus (referred
to as estrogen-lymphoma). The other two estrogen-
treated mice without lymphoma development were
referred to as estrogen-“normal” to distinguish them.
The two surviving estrogen-lymphoma mice displayed
distinct and different pathological changes that were
not usually observed after estrogen treatment. One had
markedly enlarged spleen, thymus, and liver, and the
other had a hardened thymus and stomach knot. Since
these pathological changes and lymphoma development
were not expected in our vast experience with estrogen-
treated mouse model, we excluded these two estrogen-
lymphoma mice in the main body of study. Nonetheless,
the data from the estrogen-lymphoma mice was analyzed
separately (please see Additional file 1: Figure S2 for
details). Despite the lymphoma development and other
pathological changes, these two estrogen-lymphoma
mice displayed similar increases for some lupus-associated
miRNAs such as miR-182-96-183 as estrogen-normal
mice. However, these two estrogen-lymphoma mice dis-
played large variations in expression of other miRNAs
such as miR-127, miR-327, and miR-31 (Additional file 1:
Figure S2). We recognized that the limited sample size
of estrogen-treated mice does not allow us to draw firm
conclusions. However, our data tends to support that
estrogen treatment promoted the expression of selectedlupus-associated miRNAs such as the miR-182 cluster,
miR-379, and miR-148a in orchidectomized male NZB/
WF1 mice.
Previous reports have investigated the sexual dimorphism
of protein-coding gene expression and the effect of sex
hormones in the regulation of protein-coding genes
with focus on immune response genes in both human
and mouse immune cells [50-52]. In this study, we are
the first to show sex differences in the expression of
small, non-protein-coding RNAs (miRNAs) in lupus-
prone NZB/WF1 mice. Further integration of sexually
dimorphic miRNA and messenger RNA (mRNA) gene
expression data together should provide us a compre-
hensive understanding of the molecular mechanism of
sex differences in immune function and autoimmune
disease susceptibility. In addition, further in-depth investi-
gation of the causative relationship between dysregulated
lupus-associated miRNA expression and lupus mani-
festation is warranted to understand the pathogenic
contribution of miRNAs to autoimmune lupus, which
is still in its infancy stage.
Conclusions
The core purpose of this study was to address whether
or not there are sex differences in the expression of
lupus-associated miRNAs. To this end, our study clearly
demonstrated the existence of sexual dimorphism of
lupus-associated miRNA expression in NZB/WF1 mice,
which was more evident after the onset of lupus. To our
knowledge, this is the first report of sexually dimorphic
expression of lupus-associated miRNAs in the context
of autoimmune lupus. Further, our initial study also
demonstrated that estrogen exposure accelerated the
expression of select lupus-associated miRNAs in castrated
male NZB/WF1 mice, thereby conferring male NZB/WF1
mice a female expression pattern of these miRNAs.
These novel observations provide us new insight into
the role of sexually dimorphic miRNA expression in
the sex bias of autoimmune diseases.
Additional file
Additional file 1: Supplemental data. The expression of miR-223 and
miR-451 in splenocytes was not increased with lupus manifestation in
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select lupus-associated miRNAs in estrogen-treated mice with lymphoma
development (Figure S2).
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